OrthoSera GmbH recently announced that the pilot clinical study for their hyperacute serum therapy, hypACT, shows promise for treating osteoarthritis by reversing inflammation and inducing cartilage and bone marrow turnover.
The study included 36 patients with intermediate-stage knee osteoarthritis. The proprietary blood derivative was produced at the bedside of each patient with the CE-marked hypACT inject autologous device and then administered into the knee joint.
The patients received three consecutive injections and then afterwards the researchers measured the synovial cytokine patterns, performed MR imaging and measured patient-reported outcomes. The primary goal of the study was to analyze the cytokine change of the synovial fluid.
The researchers reported that they found clear patterns that relate to the etiology of the disease. According to the data, the patients improved by an average 18 points on the Knee Injury and Osteoarthritis Outcome Score (KOOS) at six months.
“We are encouraged by this pilot data set and will continue clinical development” said Dr. Zsombor Lacza, Founder and CEO of OrthoSera.
“This was a huge undertaking and required us to measure basically all possible synovial cytokines that can play a role in osteoarthritis. The effort payed back with exciting new knowledge, as we were able to identify specific patient subgroups which can ultimately lead to targeted serum protocols that have a reliable response in knee osteoarthritis.”